Wat-Not Staff
Cardiac Amyloidosis
It is a condition of deposition of Amyloid proteins in the heart tissue, which can lead to restrictive cardiomyopathy. The heart can be affected by ATTR Amyloidosis, AL Amyloidosis, AA Amyloidosis, these are some types of Amyloidosis that can affect the heart very badly. It is crucial to manage the Cardiac Amyloidosis for a healthy life.
Vutrisiran for Cardiac Amyloidosis
Vutrisiran is a RNA interference, especially developed for the treatment of Cardiac Amyloidosis .It is designed to reduce the production of TTR protein, helps to reduce the formation of Amyloids deposit. Vutrisiran has been under testing for its safety and efficacy to use on patients.
Current Status: Positive Outlook
Vutrisian Has shown promising results for the treatment of Cardiac Amyloidosis. According to the recent reports, Alnylam has a positive outcome under phase 3 trial. The HELIOS-B study met the endpoint, showing a 28% reduction in the composite all-cause mortality and recurrent Cardiovascular events, and a 33% reduction in the monotherapy population.
It is found that Vutrisian will not cause any harm, is tolerable
Press Release
According to the Pushkal Garg, a MD,Chief Medical officer at Alnylam said “I’m thrilled by these overwhelming positive data from HELIOS-B study, which suggest that Vutrisiran has the potential to address the needs of patients with transthyretin-mediated amyloidosis with cardiomyopathy, a steadily progressive, debilitating, and ultimately fatal disease.” He added “The results showed that vutrisiran improved cardiovascular outcomes, including survival, function, and quality of life, in all patient groups with transthyretin-mediated amyloidosis cardiovascular. We are moving with urgency to file these compelling data with regulators to bring this medicine to patients around the world.”
Another Chief executive officer at Alnylam, Yvonne Greenstreet, a MBChB said “ The results suggest the potential for Vutrisiran to be transformative medicine for patients with transthyretin-mediated amyloidosis with cardiomyopathy.” In addition, he said “ Vutrisiran has the potential to become the new standard of care for the treatment of the disease.”
In summary, Vutrisiran after several trials has a positive result in Cardiac Amyloidosis. It can be used upon patients for the treatment of disease.
Follow Wat-Not on Facebook, Twitter, and Instagram
GIPHY App Key not set. Please check settings